# SeaStar Medical (ICU) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/ICU
## Company Profile
- Ticker: ICU
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: MedTech
## Stock Data
- Close: 3.05 USD
- Market cap: 14109417.059999999 USD
- Last updated: 2026-08-06
## Business Overview
### Organ-Failure Immunomodulation Company
SeaStar Medical develops extracorporeal therapies for critically ill patients with organ failure and dysregulated inflammation.
### Selective Cytopheretic Device
The Selective Cytopheretic Device is incorporated into continuous renal replacement therapy circuits and is designed to reduce the activity of inflammatory immune cells.
### QUELIMMUNE
QUELIMMUNE is authorized for pediatric acute kidney injury and is being adopted by children’s hospitals under a Humanitarian Device Exemption.
### Adult AKI Program
The pivotal NEUTRALIZE-AKI trial is evaluating the SCD in adults with acute kidney injury requiring continuous renal replacement therapy.
## Why The Stock Is Moving

The latest company update was “SeaStar Medical to Report Second Quarter Financial Results on August 12, 2026”. ICU changed 0.99% and closed at $3.05 on Aug 6, 2026, indicating a relatively limited closing-price reaction to this earnings update.

## Future Catalysts

- Completion of enrollment in the pivotal NEUTRALIZE-AKI trial is targeted around year-end 2026.
- SeaStar plans to begin submitting PMA modules to the FDA as the adult AKI program progresses, with a potential full PMA filing in 2027.

## Recent News
- 2026-08-06 12:35 EST — [SeaStar Medical to Report Second Quarter Financial Results on August 12, 2026](https://biopharmsignal.com/news/ICU/seastar-medical-to-report-second-quarter-financial-results-on-august-12-2026-23d1e391) — Source: SeaStar Medical
- 2026-07-14 12:34 EST — [SeaStar Medical Supports Advances in Critical Care of Pediatric Patients with Acute Kidney Injury (AKI)](https://biopharmsignal.com/news/ICU/seastar-medical-supports-advances-in-critical-care-of-pediatric-patients-with-ac-66530222) — Source: SeaStar Medical
- 2026-06-23 12:25 EST — [SeaStar Medical Announces New ICD-10-PCS Codes for Its SCD Therapy for Acute Kidney Injury](https://biopharmsignal.com/news/ICU/seastar-medical-announces-new-icd-10-pcs-codes-for-its-scd-therapy-for-acute-kid-ac132d55) — Source: SeaStar Medical
- 2026-06-22 12:45 EST — [SeaStar Medical to Present at Upcoming Investor Summit Conference](https://biopharmsignal.com/news/ICU/seastar-medical-to-present-at-upcoming-investor-summit-conference-599d1254) — Source: SeaStar Medical
- 2026-05-13 20:05 EST — [SeaStar Medical Reports First Quarter Financial Results and Provides Business Updates](https://biopharmsignal.com/news/ICU/seastar-medical-reports-first-quarter-financial-results-and-provides-business-up-cbbf2b30) — Source: SeaStar Medical